Targeting the weight within: obesity pharmacotherapy in cardiovascular disease Medicine Today Cagrilintide and semaglutide together drive record weight loss in global trial Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Tirzepatide Peptide: Dosage, Benefits & Effects Peptide Schedule Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine